Trial intelligence / Profile preview

SNAP study

NL-OMON27630Not yet recruiting

Sponsor
Erasmus MC
Start
Sep 2017
Modality
Small Molecules
Countries
1
01

Overview

Open-label, single-arm trial of entecavir and tenofovir in Chronic Hepatitis B (CHB), sponsored by Erasmus MC. Primary endpoint: Sustained response at week 48. Planned start Sep 2017; status: not yet recruiting.

02

Drugs

entecavirtenofovir
03

Conditions

Chronic Hepatitis B (CHB)

Beyond the preview

Go deeper on NL-OMON27630.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON27630.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call